NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.85 -0.29 (-3.56 %)
(As of 07/16/2018 02:31 PM ET)
Previous Close$8.12
Today's Range$7.85 - $8.12
52-Week Range$1.31 - $9.87
Volume7,480 shs
Average Volume911,249 shs
Market Capitalization$329.84 million
P/E Ratio-10.18
Dividend YieldN/A
Beta2.72
Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Debt-to-Equity RatioN/A
Current Ratio30.01
Quick Ratio30.01

Price-To-Earnings

Trailing P/E Ratio-10.18
Forward P/E Ratio-12.66
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.43 per share
Price / Book5.49

Profitability

EPS (Most Recent Fiscal Year)($0.80)
Net Income$-18,890,000.00
Net MarginsN/A
Return on Equity-41.07%
Return on Assets-38.45%

Miscellaneous

Employees16
Outstanding Shares40,520,000
Market Cap$329.84

The Truth About Cryptocurrencies

Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) issued its quarterly earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. View Marinus Pharmaceuticals' Earnings History.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Marinus Pharmaceuticals.

What price target have analysts set for MRNS?

7 analysts have issued 12-month price objectives for Marinus Pharmaceuticals' shares. Their predictions range from $11.00 to $33.00. On average, they anticipate Marinus Pharmaceuticals' share price to reach $18.4286 in the next twelve months. This suggests a possible upside of 133.0% from the stock's current price. View Analyst Ratings for Marinus Pharmaceuticals.

What is the consensus analysts' recommendation for Marinus Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 4,564,373 shares, an increase of 124.3% from the June 15th total of 2,034,719 shares. Based on an average daily trading volume, of 1,146,401 shares, the short-interest ratio is presently 4.0 days. Approximately 13.7% of the company's stock are short sold. View Marinus Pharmaceuticals' Current Options Chain.

Who are some of Marinus Pharmaceuticals' key competitors?

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:
  • Mr. Christopher Michael Cashman, Exec. Chairman, CEO & Pres (Age 61)
  • Mr. Edward F. Smith, CFO, VP, Treasurer & Sec. (Age 47)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 57)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations
  • Dr. Kimberly A. McCormick, Head of Regulatory Affairs

Has Marinus Pharmaceuticals been receiving favorable news coverage?

Press coverage about MRNS stock has trended positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Marinus Pharmaceuticals earned a coverage optimism score of 0.43 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 47.48 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $7.91.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $329.84 million. The biopharmaceutical company earns $-18,890,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Marinus Pharmaceuticals employs 16 workers across the globe.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 170 N. Radnor Chester Rd Suite 250, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.